Stress Urinary Incontinence (Female)
At a glance
- Assess: distinguish stress leakage from urgency, mixed or continuous leakage; document bother, demonstrate SUI with a comfortably full bladder, examine pelvic support, check urinalysis and PVR. Route urgency-predominant symptoms to the OAB pathway.[10]
- Options: discuss PFMT, an incontinence pessary, observation, and surgery according to goals. Procedural choices include midurethral sling, autologous fascial sling, Burch colposuspension and urethral bulking; discuss mesh-specific risks and likely retreatment.[10]
- Reconsider the pathway: persistent high PVR, neurological disease, prior continence surgery, inability to demonstrate the leak, significant urgency or suspected fistula warrant additional evaluation. Routine urodynamics may be omitted in an uncomplicated index patient with clearly demonstrated SUI.[10][11]
- Follow-up: review symptom benefit, new urgency, emptying, pain and adverse effects; investigate retention or new obstructive symptoms promptly. After surgery, assess satisfaction, residual leakage, examination findings and PVR.[10]
Compare the key studies. Drug regimens stay in the relevant pharmacology hubs.
Stress urinary incontinence (SUI) is the involuntary leakage of urine with physical exertion, coughing, sneezing, or any activity that raises intra-abdominal pressure. It is the most common type of urinary incontinence, affecting approximately 46% of adult women when defined as any symptoms in the previous year, with prevalence peaking at ~50% among women aged 40 and older.[2] SUI causes significant physical, emotional, and social distress and is a leading driver of gynecologic and urogynecologic referral.
ACP Guideline: The American College of Physicians recommends PFMT for stress UI, bladder training for urgency UI, and PFMT combined with bladder training for mixed UI.[1]
This page covers the clinical framework and diagnostic workup. For procedural selection and comparative treatment options, see the Female SUI treatment database.
Pathophysiology
SUI occurs when intra-abdominal pressure transiently exceeds urethral closure pressure, allowing urine to escape.[2][3] Two primary mechanisms account for most cases:
Urethral hypermobility Loss of pelvic floor muscular support or vaginal connective tissue prevents the urethra and bladder neck from assuming a stable closed position in response to pressure increases. Weakness of support structures and collagen-dependent tissue damage are central. This is the predominant mechanism in most post-partum and post-menopausal patients.
DeLancey's hammock hypothesis. The urethra rests on a supportive layer (anterior vaginal wall + endopelvic fascia) anchored laterally to the arcus tendineus and levator ani. With intact support, a cough compresses the urethra against this stable backboard and the lumen closes (continent). When the lateral (paravaginal) attachments fail, the hammock sags, the urethra becomes hypermobile, and the cough no longer compresses it — stress leakage. This is why a midurethral sling restores continence: it re-creates the suburethral backboard. (Original WARWIKI schematic)
Intrinsic sphincter deficiency (ISD) Loss of intrinsic urethral mucosal and muscular tone results in poor urethral coaptation and a reduced resting urethral closure pressure (<20–60 cmH₂O depending on criteria). ISD produces more severe leakage, often with minimal provocation, and is associated with prior urethral surgery, radiation, and neurological injury.
In practice, many patients exhibit a combination of both mechanisms.
Risk Factors
| Risk Factor | Notes |
|---|---|
| Vaginal delivery | ~2× risk vs cesarean; risk increases with parity and instrumental delivery |
| Increasing parity | Cumulative effect with each vaginal birth |
| Obesity / elevated BMI | Chronic elevated intra-abdominal pressure; weight loss reduces severity |
| Age and menopause | Estrogen deficiency reduces urethral mucosal coaptation; prevalence peaks 40–60 years |
| White race | Higher prevalence than Black or Hispanic women |
| Pelvic surgery | Hysterectomy disrupts endopelvic fascia and autonomic innervation |
| Conditions raising IAP | Chronic cough, constipation, heavy lifting, high-impact exercise |
| Smoking | Chronic cough; collagen effects |
| Connective tissue disorders | Joint hypermobility syndromes associated with PFD |
Diagnostic Evaluation
History
The Women’s Preventive Services Initiative recommends annual screening for urinary incontinence, including its impact on activities and quality of life, with further evaluation when indicated.[9]
Key elements to assess:
- Leakage pattern: Predictable with cough, sneeze, Valsalva, exercise, position change
- Severity: Frequency (daily, weekly), volume (small drops vs soaking), pad use and type
- Degree of bother: Drives treatment urgency and goal-setting
- Coexisting symptoms: Urgency, urgency incontinence, incomplete emptying, prolapse symptoms, fecal incontinence, dyspareunia
- Obstetric/surgical history: Deliveries, episiotomies, prior anti-incontinence surgery
- Medication review: Diuretics, α-blockers, anticholinergics, caffeine, alcohol
Physical Examination
| Finding | Significance |
|---|---|
| Vulvovaginal atrophy | Common in postmenopausal women; may worsen symptoms |
| Skin maceration / excoriation | Severity of leakage; hygiene counseling |
| Pelvic organ prolapse | May mask or worsen SUI; assess all three compartments |
| Pelvic floor muscle strength | Baseline for PFMT; assess ability to contract voluntarily |
| Urethral hypermobility | Cotton swab (Q-tip) test — rotation >30° from horizontal indicates hypermobility |
| Urethral diverticulum / fistula | Rule out anatomical causes of leakage |
Urinalysis
Mandatory to exclude UTI, hematuria, glycosuria, and pyuria before attributing symptoms to SUI.[2][3]
Voiding Diary
A 1–3 day fluid intake and voiding diary identifies modifiable factors (total intake, caffeine, nocturnal patterns) and quantifies leakage frequency when history is insufficient.[3]
Cough Stress Test
With the bladder comfortably full (not immediately after voiding), ask the patient to cough or Valsalva in standing or lithotomy position. Immediate urethral leakage synchronous with the cough confirms SUI. Positive predictive value 78–97%.[2][3]
Postvoid Residual
Performed by catheterization or bladder ultrasound. Important before surgical planning to exclude incomplete emptying.
Urodynamic Testing
Urodynamics may be omitted for an uncomplicated index patient with clearly demonstrated SUI. ValUE supports office evaluation alone in its selected population; its PVR eligibility threshold is not a universal safety cutoff. A single PVR does not by itself establish or exclude emptying dysfunction. Consider additional evaluation, including urodynamics when it can change management, for:[10][11]
- Mixed incontinence with significant urgency component
- Prior anti-incontinence surgery (failed or new evaluation)
- Neurogenic lower urinary tract dysfunction
- Elevated PVR or voiding dysfunction
- Discordance between symptoms and examination findings
Treatment
Step 1 — Conservative (First-Line)
Pelvic Floor Muscle Training (PFMT)
The cornerstone of first-line management and the ACP-recommended initial treatment for all women with SUI.[1] PFMT involves repeated voluntary pelvic floor contractions taught and supervised by a trained physiotherapist or pelvic health specialist.
Key evidence:
- PFMT improves patient-reported cure/improvement and condition-specific quality of life versus control; effects depend on the population and outcome assessed.[7]
- Adding PFMT to another active treatment is a separate comparison: the 2015 review found insufficient evidence for a general additional benefit across those combinations.[4]
- ~50% of women with stress-predominant incontinence are satisfied at 1 year with supervised PFMT[6]
- More intensive programs with adherence support are more effective than unsupervised instruction[7]
- Agree on the patient’s goals and distinguish complete dryness, meaningful symptom reduction and satisfaction; a ≥50% episode reduction is a study outcome definition, not a universal definition of success.[1]
Adjunctive physical therapy modalities:
| Modality | Evidence |
|---|---|
| Biofeedback | May help teach or monitor a contraction; do not promise additional long-term benefit for every patient |
| Vaginal cones | Weighted resistance training; modest benefit |
| Electrical stimulation | Benefits quality of life outcomes |
| Intravaginal pessaries | Incontinence ring/dish type; improves QoL; may be combined with PFMT |
Lifestyle Modifications
| Modification | Rationale |
|---|---|
| Weight loss | Even 5–10% reduction improves SUI in overweight/obese women[6][7] |
| Fluid management | Individualize intake to clinical needs and the diary; avoid both excess intake and dehydration |
| Caffeine reduction | Even 1 cup/day associated with incontinence; trial of elimination warranted |
| Reduce nocturnal fluids | For nocturia-associated symptoms |
| Frequent voiding | Reduce bladder volume at times of activity |
| Constipation management | Reduces chronic Valsalva and pelvic floor strain |
Surgical options
Offer surgical counselling when desired after discussing conservative and operative choices, individual risks and goals; conservative treatment failure is not a universal prerequisite.[10]
Midurethral Slings (Synthetic Mesh)
Midurethral slings have substantial efficacy evidence, but “success” depends on its definition. In TOMUS, retropubic and transobturator slings met the prespecified equivalence criterion for objective 12-month success; subjective success did not meet equivalence. Discuss retention/voiding dysfunction, pain or neurologic symptoms, mesh complications and retreatment alongside expected benefit.[12]
Comparisons with fascial sling, Burch and bulking require procedure-specific evidence and patient selection; these operations should not be described as universally equivalent.[10]
Note on mesh: FDA actions (2011, 2019) restricted transvaginal mesh for prolapse but midurethral slings for SUI retain regulatory approval given favorable risk-benefit data. Mesh-related concerns have increased patient hesitancy; informed discussion is essential.[8]
Types of midurethral slings:
| Type | Approach | Notes |
|---|---|---|
| Retropubic (TVT) | Behind pubic bone | Highest long-term data; bladder injury risk ~3–5% |
| Transobturator (TOT/TVT-O) | Lateral obturator | Lower bladder injury risk; higher groin/thigh pain rate |
| Single-incision mini-sling | Anchored midurethral | Shorter procedure; long-term data still maturing |
Autologous Fascial Sling
Pubovaginal sling using rectus fascia or fascia lata. Established robust evidence; preferred when mesh is contraindicated or patient declines synthetic materials. Higher voiding dysfunction rate than midurethral slings; durable long-term results.[8][10]
Burch Colposuspension
Open or laparoscopic retropubic colposuspension uses paravaginal sutures to Cooper's ligament. It is an established alternative to a sling; efficacy, adverse effects and durability should be discussed using the specific comparison and follow-up interval rather than assuming equivalence. Concomitant continence surgery at abdominal sacrocolpopexy is a separate shared decision, balancing postoperative leakage against added complications.[6][10]
Urethral Bulking Agents
Periurethral or transurethral injection of bulking material (polyacrylamide hydrogel, calcium hydroxylapatite, dextranomer/hyaluronic acid). Office-based, minimally invasive option. Lower cure rates than slings; useful in patients unfit for anesthesia, prior mesh failure, ISD-predominant disease, or as temporizing measure.[8]
Artificial Urinary Sphincter
Reserved for severe, complicated SUI — particularly ISD after prior failed surgery or radiation. High-quality data limited for this indication in women; see AUS article.[6]
Pharmacotherapy
Medical therapies for SUI are generally not recommended — current evidence-based pharmacological treatments primarily address urgency incontinence (antimuscarinics, β3-agonists), not SUI.[6]
Duloxetine (SNRI, not FDA-approved for SUI in the US) has modest evidence for symptom improvement but significant side effects limiting use; not in routine clinical practice in North America.
Emerging Therapies
Vaginal laser therapy (CO₂ fractional laser, Er:YAG laser) has been investigated for SUI. A 2025 Cochrane review (Ippolito et al.) provides updated evidence; this remains an evolving area without established guideline support.[5]
Outcomes
Outcome definitions and follow-up must accompany any percentage. In TOMUS, 12-month objective success was 80.8% after retropubic and 77.7% after transobturator sling; subjective success was 62.2% and 55.8%, respectively. Objective outcomes met the trial's equivalence criterion, while subjective outcomes did not. These study-specific results should not be presented as universal cure rates for every sling or compared directly with unrelated Burch, fascial-sling or bulking series.[12]
For counseling, separate symptom improvement, complete dryness, satisfaction, adverse effects and retreatment. The selected evidence records the principal trial comparisons; procedure pages contain the operation-specific evidence.
Clinical Approach Summary
A practical assessment and shared-decision checklist:[10]
- Assess bother and QoL impact — drives urgency and goals of treatment
- Quantify leakage — frequency, volume, pad use, pad weight test if available
- Pelvic exam — prolapse assessment, muscle function, Q-tip test, cough stress test
- Urinalysis — rule out UTI
- First-line: Prescribe supervised PFMT ± lifestyle modifications (weight loss, caffeine reduction)
- Adjuncts: Incontinence pessary if patient prefers non-surgical option or awaits PFMT response
- Procedure discussion when desired: Discuss sling, colposuspension, fascial sling and bulking according to goals; use additional testing according to complexity.
Referral Indications
- Significant pelvic organ prolapse (concurrent repair consideration)
- Elevated PVR / voiding dysfunction
- Failed prior anti-incontinence surgery
- Mixed incontinence with dominant urgency component
- Consideration of surgical management
- Neurological comorbidity
Selected evidence
ValUE · 2012[11]; TOMUS · 2010[12]. The comparison below preserves the study-specific population, denominator, endpoint and uncertainty.
Selected studies, not a systematic review. Outcomes and populations differ; percentages across studies should not be ranked as if they were directly comparable. These source checks do not record a clinician review of the full article.
| Study and population | Comparison and results | Use and limitations |
|---|---|---|
| ValUE · 2012 Women with uncomplicated, demonstrable stress-predominant incontinence. Randomized n=630 | Office evaluation plus urodynamics vs office evaluation alone Composite success: ≥70% UDI improvement and much/very much better on PGI-I · 12 months 76.9% with urodynamics vs 77.2% with office evaluation alone. Difference −0.3 percentage points; 95% CI −7.5 to 6.9. Prespecified noninferiority margin: 11 percentage points. | Supports omitting routine preoperative urodynamics in appropriately selected index patients.
|
| TOMUS · 2010 Women having surgery for stress urinary incontinence. Randomized n=597 | Retropubic vs transobturator midurethral sling Objective success: negative stress/pad tests and no retreatment · 12 months 80.8% vs 77.7%. Difference 3.0 percentage points; 95% CI −3.6 to 9.6; met the ±12-point equivalence margin. Subjective success: no symptoms/diary leakage or retreatment · 12 months 62.2% vs 55.8%. Difference 6.4 percentage points; 95% CI −1.6 to 14.3; did not meet equivalence. | Discuss endpoint definitions and route-specific complications; no single route is best for every patient.
|
See Also
- Female SUI treatment database
- Pelvic Floor Physical Therapy
- Behavioral Therapy for Urinary Incontinence
- Weight Loss for Urinary Incontinence
- Retropubic Mid-Urethral Sling
- Transobturator Mid-Urethral Sling
- Single-Incision Mini-Sling
- Autologous Fascial Pubovaginal Sling
- Burch Colposuspension
- Urethral Bulking Agents
- Artificial Urinary Sphincter
References
1. Qaseem A, Dallas P, Forciea MA, et al. Nonsurgical management of urinary incontinence in women: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014;161(6):429–40. PMID 25222388
2. Wu JM. Stress incontinence in women. N Engl J Med. 2021;384(25):2428–36. PMID 34161707
3. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary incontinence in women: a review. JAMA. 2017;318(16):1592–1604. PMID 29067433
4. Ayeleke RO, Hay-Smith EJ, Omar MI. Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women. Cochrane Database Syst Rev. 2015;(11):CD010551. PMID 26526663
5. Ippolito GM, Crescenze IM, Sitto H, et al. Vaginal lasers for treating stress urinary incontinence in women. Cochrane Database Syst Rev. 2025;7:CD013643. doi:10.1002/14651858.CD013643.pub2
6. ACOG Practice Bulletin No. 155: Urinary incontinence in women. Obstet Gynecol. 2015;126(5):e66–81. PMID 26488524
7. Todhunter-Brown A, Hazelton C, Campbell P, et al. Conservative interventions for treating urinary incontinence in women: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev. 2022;9:CD012337. PMID 36053030
8. Moris L, Heesakkers J, Nitti V, et al. Prevalence, diagnosis, and management of stress urinary incontinence in women: a collaborative review. Eur Urol. 2025;87(3):292–301. PMID 39848866
9. O'Reilly N, Nelson HD, Conry JM, et al. Screening for urinary incontinence in women: a recommendation from the Women's Preventive Services Initiative. Ann Intern Med. 2018;169(5):320–28. PMID 30105360
10. American Urological Association / SUFU. Surgical Treatment of Female Stress Urinary Incontinence, amended 2023. Full guideline. Accessed September 11, 2026.
11. Nager CW et al. A Randomized Trial of Urodynamic Testing before Stress-Incontinence Surgery. 2012. doi:10.1056/NEJMoa1113595.
12. Richter HE et al. Retropubic versus Transobturator Midurethral Slings for Stress Incontinence. 2010. doi:10.1056/NEJMoa0912658.